New Drug Approvals (Original) — March 17, 2026

Four ANDA approvals in tight timeframe enable sponsor market entries without innovation premiums.

Pricing pressure and multi-sponsor competition in generic ANDA markets.

Unspecified indications obscure addressable market size and revenue potential.

Near-term commercial launches from approved ANDAs to expand generic portfolios.

Uniform standard-review ANDAs with no designations highlight routine generic activity absent innovation.

{"entity"=>"Aurobindo Pharma Ltd", "reason"=>"Portfolio expansion via citalopram ANDA; routine but scalable.", "trigger"=>"Q2 2026 launch sales >$10M"}

{"entity"=>"Hetero Labs Ltd III", "reason"=>"Dextromethorphan combo approval adds to generics slate.", "trigger"=>"Competitive share gains post-launch"}

{"entity"=>"CAPLIN", "reason"=>"Potassium phosphate entry targets electrolyte niche.", "trigger"=>"Indication clarification or sales ramp"}

{"entity"=>"ORBICULAR", "reason"=>"Phytonadione approval as first-period signal.", "trigger"=>"Follow-on ANDAs or pricing execution"}